Q4 2015 13F Holders as of 12/31/2015
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
123M
-
Number of holders
-
164
-
Total shares
-
98.8M
-
Shares change
-
+330K
-
Total reported value, excl. options
-
$1.71B
-
Value change
-
+$8.21M
-
Put/Call ratio
-
0.83
-
Number of buys
-
75
-
Number of sells
-
-84
-
Price
-
$17.33
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q4 2015
173 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q4 2015.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 164 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 98.8M shares
of 123M outstanding shares and own 80.2% of the company stock.
Largest 10 shareholders include Third Security, LLC (19.8M shares), IRIDIAN ASSET MANAGEMENT LLC/CT (8.68M shares), VANGUARD GROUP INC (7.44M shares), BB BIOTECH AG (7.03M shares), FMR LLC (6.32M shares), First Eagle Investment Management, LLC (4.31M shares), BlackRock Fund Advisors (4.2M shares), STATE STREET CORP (3M shares), BlackRock Institutional Trust Company, N.A. (2.88M shares), and Invesco Ltd. (2.39M shares).
This table shows the top 164 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.